These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 7848345

  • 1. Preclinical testing of iopromide. 2nd communication: toxicological evaluation.
    Krause W, Schöbel C, Press WR.
    Arzneimittelforschung; 1994 Nov; 44(11):1275-9. PubMed ID: 7848345
    [Abstract] [Full Text] [Related]

  • 2. Preclinical testing of iopromide. 1st communication: pharmacological evaluation.
    Krause W, Press WR, Frenzel T.
    Arzneimittelforschung; 1994 Oct; 44(10):1162-6. PubMed ID: 7529504
    [Abstract] [Full Text] [Related]

  • 3. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist).
    Döhr O, Hofmeister R, Treher M, Schweinfurth H.
    Invest Radiol; 2007 Dec; 42(12):830-41. PubMed ID: 18007155
    [Abstract] [Full Text] [Related]

  • 4. Preclinical characterization of iopromide-carrying liposomes.
    Krause W, Sachse A, Wagner S, Kollenkirchen U, Rössling G.
    Invest Radiol; 1991 Nov; 26 Suppl 1():S172-4; discussion S175-6. PubMed ID: 1808120
    [No Abstract] [Full Text] [Related]

  • 5. Characterization of continuously extruded iopromide-carrying liposomes for computed tomography blood-pool imaging.
    Leike JU, Sachse A, Rupp K.
    Invest Radiol; 2001 Jun; 36(6):303-8. PubMed ID: 11410749
    [Abstract] [Full Text] [Related]

  • 6. [Preclinical toxicological study of D-glucuronic acid].
    Karpova GV, Fomina TI, Vetoshkina TV, Borovskaia TG, Voronova OL, Dubskaia TIu, Udut VV, Khlusova MIu.
    Eksp Klin Farmakol; 2001 Jun; 64(1):68-70. PubMed ID: 11544811
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients.
    Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD.
    Acta Radiol; 2008 Oct; 49(8):902-11. PubMed ID: 18651252
    [Abstract] [Full Text] [Related]

  • 8. Toxicological safety evaluation of gadobutrol.
    Wack C, Steger-Hartmann T, Mylecraine L, Hofmeister R.
    Invest Radiol; 2012 Nov; 47(11):611-23. PubMed ID: 23011188
    [Abstract] [Full Text] [Related]

  • 9. Toxicologic profile of iobitridol, a new nonionic low-osmolality contrast medium.
    Donandieu AM, Idee JM, Doucet D, Legros A, Penati S, Nain-Dit-Ducret M, Marmion F, Bonnemain B.
    Acta Radiol Suppl; 1996 Nov; 400():17-24. PubMed ID: 8619348
    [Abstract] [Full Text] [Related]

  • 10. Neurotolerability of nonionic X-ray contrast media. The role of chemotoxicity.
    Luzzani F, Morisetti A, Bussi S, Tirone P, de Haën C.
    Invest Radiol; 1996 Jun; 31(6):338-44. PubMed ID: 8761866
    [Abstract] [Full Text] [Related]

  • 11. Neurotoxicity of non-ionic X-ray contrast media after intracisternal administration in rats.
    Wible JH, Barco SJ, Scherrer DE, Wojdyla JK, Adams MD.
    Eur J Radiol; 1995 Mar; 19(3):206-11. PubMed ID: 7601172
    [Abstract] [Full Text] [Related]

  • 12. Toxicological investigations with nimodipine. Summary of relevant studies.
    Schlüter G.
    Arzneimittelforschung; 1986 Dec; 36(12):1733-5. PubMed ID: 3566834
    [Abstract] [Full Text] [Related]

  • 13. Toxicological profile of a low molecular weight spleen peptide formulation used in supportive cancer therapy.
    Hartleb M, Leuschner J.
    Arzneimittelforschung; 1997 Sep; 47(9):1047-51. PubMed ID: 9342421
    [Abstract] [Full Text] [Related]

  • 14. Are iodinated contrast agents detrimental in acute cerebral ischemia? An experimental study in rats.
    Doerfler A, Engelhorn T, von Kummer R, Weber J, Knauth M, Heiland S, Sartor K, Forsting M.
    Radiology; 1998 Jan; 206(1):211-7. PubMed ID: 9423675
    [Abstract] [Full Text] [Related]

  • 15. Ondansetron: pre-clinical safety evaluation.
    Tucker ML, Jackson MR, Scales MD, Spurling NW, Tweats DJ, Capel-Edwards K.
    Eur J Cancer Clin Oncol; 1989 Jan; 25 Suppl 1():S79-93. PubMed ID: 2533905
    [Abstract] [Full Text] [Related]

  • 16. Toxicity studies with flutrimazole.
    Vericat ML, García Rafanell J, Forn J, Casadesús A, Alumá J, Zapatero J.
    Arzneimittelforschung; 1992 Jun; 42(6):841-6. PubMed ID: 1418043
    [Abstract] [Full Text] [Related]

  • 17. Toxicological properties of metaflumizone.
    Hempel K, Hess FG, Bögi C, Fabian E, Hellwig J, Fegert I.
    Vet Parasitol; 2007 Dec 15; 150(3):190-5. PubMed ID: 17933467
    [Abstract] [Full Text] [Related]

  • 18. Toxicological safety assessment of iomeprol, a new X-ray contrast agent.
    Morisetti A, Tirone P, Luzzani F, de Haën C.
    Eur J Radiol; 1994 May 15; 18 Suppl 1():S21-31. PubMed ID: 8020516
    [Abstract] [Full Text] [Related]

  • 19. [The tolerability of pale sulfonated shale oil following local and systemic administration].
    Cholcha W, Leuschner J, Leuschner F.
    Arzneimittelforschung; 1994 Feb 15; 44(2):170-7. PubMed ID: 7908523
    [Abstract] [Full Text] [Related]

  • 20. The rabbit renal toxicity test: a sensitive in vivo test for the nephrotoxicity of contrast agents.
    Pettersson G, Towart R, Grant D, Thyberg K, Golman K.
    Acad Radiol; 2002 May 15; 9 Suppl 1():S62-4. PubMed ID: 12019897
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.